Study (years) | Phase | Treatment | Patients (n) | OS (months) | PFS (months) | DOR (months) | OR (%) | Ref. |
---|---|---|---|---|---|---|---|---|
Cortes et al. (2011) [13] | III | Eribulin mesylate vs TPC | 508 vs 254 | 13.1 | 3.7 | 3.9 | 13 | [6] |
Kaufman et al. (2012) [10] | III | Eribulin mesylate vs Capecitabine | 554 vs 548 | 15.9 | 4.2 | 4.1 | 11 | [10] |
Ramaswami et al. (2014) [16] | IV | Eribulin mesylate | 25 | 5.89 | 4.08 | - | 16 | [16] |
Poletti et al. (2014) [17] | IV | Eribulin mesylate | 27 | 8 | - | 2.5 | 9 | [17] |
Gamucci et al. (2014) [18] | IV | Eribulin mesylate | 133 | 14.3 | 4.4 | 5.2 | 21.1 | [18] |
Rasmussen et al. (2014) [19] | IV | Eribulin mesylate | 44 | - | - | - | 12.5 | [19] |
Present study | IV | Eribulin mesylate | 258 | 11.2 | 3.8 | 4.4 | 26 |